Proteor has secured investments from Eurazeo, Crédit Mutuel Equity, Bpifrance, and BNP Paribas Développement to further its international growth and innovation in the orthopedic sector, marking the exit of Ardian.

Target Information

On September 22, 2025, Proteor, a well-known player in the orthopedics market, welcomed Eurazeo through its Nov Santé Actions Non Cotées fund, alongside Crédit Mutuel Equity, Bpifrance, and BNP Paribas Développement, who is reinvesting in this transaction, marking the exit of Ardian, a minority shareholder since 2021. Under the leadership of Edouard Archambeaud, a fourth-generation member of the founding Pierron family, Proteor reported a revenue of approximately €170 million and employs around 1,100 staff members. The family-owned company aims to accelerate its growth both in France and internationally while maintaining independence and committed to improving the autonomy and quality of life for patients.

Founded in 1913 in Saint-Apollinaire (Côte-d'Or), Proteor has established itself as a major actor in the design, manufacturing, and distribution of external prosthetics, predominantly lower limb prostheses. The company is also recognized for its software suite and 3D printers that assist orthoprothetic professionals. Initially specialized in operating a network of orthoprothetics centers, known for their service and quality, Proteor has gradually diversified into the development and manufacturing of prostheses, thereby positioning itself across the entire value chain.

Industry Overview

The global prosthetics and orthotics market is witnessing continuous growth and evolution, a trend that benefits Proteor significantly. Demand is driven by advancements in innovative technological s